Answers are grounded in this paper and cite their sources.
Background This study aimed to validate a Composite Pain Index (CPI) as a single pain outcome measure for sickle cell disease (SCD) across the lifespan from 8 years of age. Procedure This prospective, cross‐sectional study included 55 participants with SCD who completed the PAIN Report It tool and Adolescent Pediatric Pain Tool (APPT) in random order during outpatient visits to derive respective CPI scores for comparison. Results Of the 55 participants with SCD, 46 (84%) had HgbSS, eight (15%) HgbSC, and one (2%) HgbSβ0 + . The mean age of all participants was 17.5 ± 2.6 years, and 28 (51%) were female, 52 (95%) were Black, 42 (98%) were non‐Hispanic, and 39 (71%) had a ninth grade or higher education. Correlation analyses between the APPT and PAIN Report It revealed positive associations for the number of pain sites ( r = .57, p < .001), pain intensity ( r = .46, p < .001), pain quality ( r = .74, p < .001), and pain pattern ( r = .34, p = .01). Patients’ mean CPI scores derived from the PAIN Report It was slightly higher than the APPT; 34.2 (SD = 14.7) and 30.0 (SD = 19.0), respectively. Regression analyses showed that the APPT CPI significantly predicted the PAIN Report It CPI ( B = .497, t (53) = 6.051, p < .001). This finding holds true even when accounting for the order of measurement or patient's age. Conclusion The initial validation of CPI as a single pain outcome measure represents a significant advancement in pain assessment for SCD. Further validation is warranted for the CPI as a measure is for both clinicians and researchers to enable longitudinal pain assessment from age 8 years across the lifespan as children age into adult care.
No takes yet. Share an insight, caveat, or question.
Kashif et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: